Elizabeth J McFarland MD

Pediatric Infectious Disease•Aurora, CO

Professor, Pediatrics, University of Colorado School of Medicine

Join to View Full Profile

13123 E 16th AveAurora, CO 80045
Phone+1 720-777-1234

Education & Training

University of ColoradoFellowship, Pediatric Infectious Diseases, 1992
University of ColoradoResidency, Pediatrics, 1985 - 1988
Duke University School of MedicineClass of 1985

Certifications & Licensure

CO State Medical License 1987 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Infectious Diseases

Clinical Trials

Effects of Home Visits on Medication Adherence in Children and Youth With HIV
Unknown status
Not Applicable
Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults
Withdrawn
Phase 1, Phase 2
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women Start of enrollment: 2010 Jan 01
Completed
Phase 4
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
RECRUITING
Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention Start of enrollment: 2011 Nov 01
Completed
Not Applicable
An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) Start of enrollment: 2013 Mar 01
Completed
Phase 2
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants Start of enrollment: 2013 Aug 26
Terminated
Phase 2, Phase 3
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV Start of enrollment: 2014 Jan 16
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)
RECRUITING
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Start of enrollment: 2014 Sep 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1.
Coleen K Cunningham, Elizabeth J McFarland, Petronella Muresan, Edmund V Capparelli, Charlotte Perlowski
Journal of the Pediatric Infectious Diseases Society. 2025-02-06
Bone Accrual Trajectories in Children and Adolescents with Perinatal HIV Infection.
Linda Anne DiMeglio, Wendy Yu, Heidi J Kalkwarf, Sean Brummel, Janet S Chen
The Journal of Clinical Endocrinology and Metabolism. 2024-09-23
20 citations
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children.
Coleen K Cunningham, Ruth A Karron, Petronella Muresan, Matthew S Kelly, Elizabeth J McFarland
The Journal of Infectious Diseases. 2022-12-13

Journal Articles

Development and Application of a Multiplex Assay for the Simultaneous Measurement of Antibody Responses Elicited by Common Childhood Vaccines
Elizabeth J McFarland, Coleen K Cunningham, William Borkowsky, Sallie R Permar, ScienceDirect

Elizabeth J McFarland MD

Dr. McFarland is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.